$1.96
1.55%
Nasdaq, Oct 09, 04:00 pm EDT. Closed.
ISIN
US49720K1016
Symbol
HURA

Kintara Therapeutics Inc Stock price

$1.96
-0.05 2.49% 1M
+0.00 0.00% 6M
+1.20 159.02% YTD
-0.62 24.03% 1Y
-60.69 96.87% 3Y
-728.49 99.73% 5Y
-50,660.54 100.00% 10Y
-1,546.79 99.87% 20Y
Nasdaq, Closing price Fri, Oct 09 2026
+0.03 1.55%
ISIN
US49720K1016
Symbol
HURA
Industry

Is Kintara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
$124.9m
Enterprise Value
$127.5m
Net debt
$2.6m
Cash
$1.0m
Shares outstanding
63.7m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
6.8
Financial Health
Equity Ratio
76.5%
Return on Equity
-143.6%
ROCE
-139.5%
ROIC
-
Debt/Equity
0.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$8.5m | -
SBC as % of FCF
-
SBC Growth 1Y
78.1%
Share Count Growth 1Y
27.6%
Shareholder Yield
-27.6%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-31.3m
EBIT
$-31.4m
Net Income
$-30.6m
Free Cash Flow | ex SBC
$-29.9m | $-38.4m
Growth
Revenue | estimate
- | -
EBITDA
9.0%
EBIT
9.2%
Net Income
21.1%
Free Cash Flow
-15.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
12.4%
Employees
22
Rev per Employee
$0.0

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Kintara Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Kintara Therapeutics Inc forecast:

Buy
90%
Hold
10%

Kintara Therapeutics Inc Events

Past Events
AUG
18
Shareholder/Analyst Call - TuHURA Biosciences, Inc.
about 2 months ago

Financial data from Kintara Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.64 4.64
60% 60%
-
- Research and Development Expense 23 23
0% 0%
-
-31 -31
9% 9%
-
- Depreciation and Amortization 0.10 0.10
29% 29%
-
EBIT (Operating Income) EBIT -31 -31
9% 9%
-
Net Profit -31 -31
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kintara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kintara Therapeutics Inc Stock News

Neutral
PRNewsWire
●
7 days ago
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T,  Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the Unite...
Neutral
PRNewsWire
●
28 days ago
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting...
Neutral
PRNewsWire
●
about 2 months ago
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.
More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Bianco
Employees 22
Founded 2009
Website tuhurabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today